Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580518 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL24471174 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL9113490 | 0.79 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2796319 | 0.77 | ARNT (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16372373 | 0.71 | ARNT (0.31) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL24758155 | 0.71 | SCN9A (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL29020744 | 0.69 | KDM4E (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16718843 | 0.69 | KDM4E (0.32) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1710773 | 0.69 | SCN9A (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL9966755 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc., a fully owned subsidiary of Merck Sharp & Dohme LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-115175905-B | ZESTE enhancer homolog 2 inhibitors and uses thereof | 西藏海思科制药有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-3953331-B1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| CN-115175905-A | ZESTE enhancer homolog 2 inhibitors and uses thereof | 四川海思科制药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022115521-A1 | (HETEO)ARYL SUBSTITUTED PYRROLO-, PYRAZOLO- AND TRIAZOLOPYRIDAZINE DERIVATES AS MAT2A INHIBITORS | SERVIER PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2013092976-A1 | NEW PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| CN-102007123-A | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2011-04-06 | — | — | CN | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDM4E 683/4885USP2 2770/4885ALDH1A1 451/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | KDM4E 404/4885USP2 1256/4885ALDH1A1 4805/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | KDM4E 404/4885USP2 1256/4885ALDH1A1 4805/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | KDM4E 404/4885USP2 1256/4885ALDH1A1 4805/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | KDM4E 22/4885USP2 1220/4885ALDH1A1 1788/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | KDM4E 683/4885USP2 2770/4885ALDH1A1 451/4885 |
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | RBM39, RBM3, RBM28 | KDM4E 1516/4885USP2 1737/4885ALDH1A1 3897/4885 |
| US-20130165444-A1 | Piperidine Derivatives | PPARD, FABP4, PLIN5 | KDM4E 792/4885USP2 2879/4885ALDH1A1 621/4885 |
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | KDM4E 1862/4885USP2 3871/4885ALDH1A1 172/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | KDM4E 2509/4885USP2 1715/4885ALDH1A1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.